Floatz logo

Semaglutide

Diabetes Type 2

University of Maryland, Baltimoreprotein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Diabetes Type 2 cohort.

Asset / SponsorPhaseRating
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Liraglutide
RenJi Hospital
Phase 4BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →